GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT07057310

Enrolling by invitationPhase 4

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Lead sponsor

Mayo Clinic

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Obesity / overweight, Reproductive / infertility

Key I/E criteria

•BMI ≥30•Female

Primary endpoints

•Physical Function Measure•6-minute walk distance•SF-36 total

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07057310

Org study ID24-010834

Timeline

Milestones

Study start2025-05-01actual

Study first posted2025-07-09actual

Last update posted2025-07-09actual

Primary completion2026-12-31estimated

Study completion2027-03-31estimated

Assets

Investigational agents

Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweightReproductive / infertility

Eligibility

Who can enroll

Minimum age46 Years

Maximum age60 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy)

•Age 46-60 years old

•BMI ≥ 30 kg/m2.

Exclusion criteria

•Past or current use of menopausal hormone therapy

•Early or premature menopause

•History of chemically induced menopause

•Impaired renal function (GFR ≤29)

•Thyroid-stimulating hormone ≥7 with low free T4

•Diabetes

•Cardiovascular disease

•Elevated blood pressure (>170/>95)

•Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease

•>5% change in weight during the 3 months prior to screening

•Other anti-obesity medication use within the past 3 months

•History of bariatric surgery

•History of malignant neoplasms within the past 5 years prior to screening

•Current use of supplements known to affect weight

•Personal or family history of medullary thyroid cancer.

•Wheelchair bound

•Vision loss

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Patient-reported / QoL

Other (unclassified)

Heart failure

Cardiometabolic biomarkers

Heart failure

1 endpoint

Primary/protocol endpoint

Physical Function Measure: Six-Minute Walk Test (6MWT)

Time frame:24 weeks

6-minute walk distance

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Primary/protocol endpoint

Vascular Function Assessment: Reactive Hyperemia Index (RHI) using EndoPAT

Time frame:24 weeks

change from baseline, improvement

Patient-reported / QoL

2 endpoints

Primary/protocol endpoint

Physical Function Measure: Short Form-12 (SF-12) Health Survey

Time frame:24 weeks

SF-36 total

descriptive, improvement

Primary/protocol endpoint

Physical Function Measure: Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue and Physical Function Domains

Time frame:24 weeks

descriptive, improvement

Other clinical outcomes

5 endpoints

Primary/protocol endpoint

Physical Function Measure: Short Physical Performance Battery (SPPB) score.

Time frame:24 weeks

change from baseline, improvement

Primary/protocol endpoint

Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat

Time frame:24 weeks

descriptive

Primary/protocol endpoint

Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST)

Time frame:24 weeks

change from baseline, improvement

Primary/protocol endpoint/low confidence

Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST)

Time frame:24 weeks

change from baseline, improvement

Primary/protocol endpoint

Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer

Time frame:24 weeks

descriptive

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Aging Biomarkers: Cellular Senescence Markers in Plasma

Time frame:24 weeks

concentration, descriptive

Primary/protocol endpoint/low confidence

Difference between biological and chronological age

Time frame:24 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.